News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,328 Results
Type
Article (14287)
Company Profile (281)
Press Release (254760)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79553)
Career Advice (153)
Deals (13234)
Drug Delivery (35)
Drug Development (50474)
Employer Resources (31)
FDA (5730)
Job Trends (5140)
News (144476)
Policy (10034)
Tag
Academia (916)
Accelerated approval (3)
Adcomms (13)
Allergies (52)
Alliances (21690)
ALS (69)
Alzheimer's disease (854)
Antibody-drug conjugate (ADC) (110)
Approvals (5757)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (61)
Brain cancer (20)
Breast cancer (165)
Cancer (1546)
Cardiovascular disease (122)
Career advice (134)
Career pathing (2)
CAR-T (127)
Cell therapy (349)
Cervical cancer (9)
Clinical research (41211)
Collaboration (568)
Compensation (286)
Complete response letters (13)
COVID-19 (1036)
CRISPR (47)
C-suite (173)
Cystic fibrosis (78)
Data (1654)
Denatured (11)
Depression (32)
Diabetes (146)
Diagnostics (1304)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (88)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (96)
Earnings (30291)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48879)
Executive appointments (478)
FDA (6517)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (525)
Gene editing (106)
Generative AI (10)
Gene therapy (277)
GLP-1 (375)
Government (1084)
Grass and pollen (2)
Guidances (75)
Healthcare (6596)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (20)
Infectious disease (1103)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7282)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1388)
Liver cancer (34)
Lung cancer (212)
Lymphoma (107)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (65)
Medical device (2604)
Medtech (2605)
Mergers & acquisitions (6297)
Metabolic disorders (416)
Multiple sclerosis (55)
NASH (13)
Neurodegenerative disease (78)
Neuropsychiatric disorders (26)
Neuroscience (1291)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (23)
Obesity (201)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (126)
Partnered (8)
Patents (141)
Patient recruitment (85)
Peanut (35)
People (25695)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14566)
Phase II (19180)
Phase III (12102)
Pipeline (1007)
Policy (49)
Postmarket research (852)
Preclinical (6173)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (303)
Real estate (1420)
Recruiting (12)
Regulatory (8683)
Reports (18)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (6)
RNA editing (8)
RSV (10)
Schizophrenia (64)
Series A (103)
Series B (71)
Service/supplier (1)
Sickle cell disease (43)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (219)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (87)
Last 7 days (599)
Last 30 days (2094)
Last 365 days (19343)
2025 (7495)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23358)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11840)
2015 (14352)
2014 (10394)
2013 (7485)
2012 (7533)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (44)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17364)
Australia (2948)
California (4195)
Canada (1197)
China (380)
Colorado (160)
Connecticut (157)
Delaware (112)
Europe (37399)
Florida (510)
Georgia (128)
Idaho (16)
Illinois (245)
India (10)
Indiana (94)
Iowa (3)
Japan (83)
Kansas (64)
Kentucky (5)
Louisiana (4)
Maine (11)
Maryland (503)
Massachusetts (3329)
Michigan (77)
Minnesota (156)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1024)
New Mexico (12)
New York (1114)
North Carolina (580)
North Dakota (6)
Northern California (1875)
Ohio (118)
Oklahoma (9)
Oregon (21)
Pennsylvania (784)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1603)
Tennessee (26)
Texas (485)
United States (14254)
Utah (56)
Virginia (87)
Washington D.C. (32)
Washington State (371)
Wisconsin (19)
269,328 Results for "entrada therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Entrada Cuts 20% of Workforce, Targeting Research Employees
Entrada is paring back its research staff even as it gears up to hire employees to support a planned clinical trial for a Duchenne muscular dystrophy candidate.
April 30, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Entrada Therapeutics Reports First Quarter 2025 Financial Results
May 9, 2025
·
10 min read
Press Releases
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
·
9 min read
Press Releases
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
February 24, 2025
·
7 min read
Deals
Entrada Therapeutics Announces $100 Million Registered Direct Offering
Entrada Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares.
June 24, 2024
·
4 min read
Genetown
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible.
June 3, 2024
·
1 min read
Business
Entrada Therapeutics Reports First Quarter 2024 Financial Results
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
May 7, 2024
·
9 min read
Press Releases
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
·
1 min read
Press Releases
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
November 5, 2024
·
10 min read
Press Releases
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
March 25, 2025
·
7 min read
1 of 26,933
Next
